Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00554606. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.
Study identification
- NCT ID
- NCT00554606
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2007 (Actual)
- Primary completion
- Aug 13, 2009 (Actual)
- Completion
- Aug 13, 2009 (Actual)
- Last update posted
- Jul 9, 2021
2007 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigator Site | Huntsville | Alabama | 35801 | — |
| Novartis Investigator Site | Tuscaloosa | Alabama | 35406 | — |
| Novartis Investigator Site | Paradise Valley | Arizona | 85253 | — |
| Novartis Investigator Site | Trumbull | Connecticut | 06611 | — |
| Novartis Investigator Site | Jacksonville | Florida | 32216 | — |
| Novartis Investigator Site | South Miami | Florida | 33143 | — |
| Novartis Investigator Site | Tamarac | Florida | 33321 | — |
| Novartis Investigator Site | Rockford | Illinois | 61107 | — |
| Novartis Investigator Site | Urbandale | Indiana | 50322 | — |
| Novartis Investigator Site | Richmond Heights | Missouri | 63117 | — |
| Novartis Investigator Site | Omaha | Nebraska | 68114 | — |
| Novartis Investigator Site | Reno | Nevada | 89502 | — |
| Novartis Investigator Site | Tulsa | Oklahoma | 74104 | — |
| Novartis Investigator Site | Austin | Texas | 78704 | — |
| Novartis Investigator Site | Carrollton | Texas | 75007 | — |
| Novartis Investigator Site | Dallas | Texas | 75246 | — |
| Novartis Investigator Site | Fort Worth | Texas | 75246 | — |
| Novartis Investigator Site | Mesquite | Texas | 75150 | — |
| Novartis Investigator Site | Arlington | Virginia | 22205 | — |
| Novartis Investigator Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00554606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00554606 live on ClinicalTrials.gov.